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Key Points: 28 
We show that Staphylococcal enterotoxins activate oncogenic pathways in CTCL. 29 
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This discovery implies a novel role of microbes as drivers of disease progression. 31 
 32 
Abstract 33 
Cutaneous T cell lymphoma (CTCL) is characterized by proliferation of malignant T cells in a chronic 34 
inflammatory environment. With disease progression, bacteria colonize the compromised skin barrier 35 
and half of CTCL patients die from infection rather than from direct organ involvement by the 36 
malignancy. Clinical data indicate that bacteria play a direct role in disease progression, but little is 37 
known about the mechanisms involved. Here, we demonstrate that bacterial isolates containing 38 
staphylococcal enterotoxin-A (SEA) from the affected skin of CTCL patients, as well as recombinant 39 
SEA, stimulate activation of STAT3 and up-regulation of IL-17 in immortalized and primary patient-40 
derived malignant and non-malignant T cells. Importantly, SEA induces STAT3 activation and IL-17 41 
expression in malignant T cells when co-cultured with non-malignant T cells indicating an indirect 42 
mode of action. In accordance, malignant T cells expressing a SEA non-responsive T cell receptor V 43 
beta chain (TCR-Vb) are non-responsive to SEA in mono-culture, but display strong STAT3 activation 44 
and IL-17 expression in co-cultures with SEA-responsive, non-malignant T cells.  The response is 45 
induced via IL-2Rg cytokines and a Janus kinase 3 (JAK3) - dependent pathway in malignant T cells and 46 
blocked by Tofacitinib, a clinical-grade JAK3 inhibitor. In conclusion, we demonstrate that SEA induces 47 
cell cross-talk-dependent activation of STAT3 and expression of IL-17 in malignant T cells suggesting a 48 
mechanism where SEA-producing bacteria promote activation of an established oncogenic pathway 49 
previously implicated in carcinogenesis.  50 
  51 
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Introduction 52 
Cutaneous T-cell lymphoma (CTCL) comprises a group of heterogeneous lymphoproliferative 53 
disorders defined by the expansion of malignant skin-homing T cells in a chronic inflammatory 54 
environment. Mycosis Fungoides and Sézary syndrome represent the most prevalent forms of CTCL
1,2
. 55 
Despite intensive research, the CTCL etiology remains elusive and the pathogenesis is far from 56 
understood. Chromosomal instability, abnormal gene expression, gene duplication, and epigenetic 57 
deregulation have been implicated in CTCL, but no single underlying genetic or epigenetic event has 58 
yet been identified as a likely cause of the disease
3-9
. Persistent activation of Signal Transducer and 59 
Activator of Transcription 3 (STAT3)
10
 has repeatedly been implicated in CTCL pathogenesis as a 60 
potent driver of survival and proliferation of malignant T cells
11-17
. Importantly, Stat3 promotes 61 
malignant expression of the proinflammatory cytokine IL-17, including a range of cytokines which 62 
have been associated with skin inflammation, immune deregulation, and disease progression
18-23
. 63 
 64 
It is well established that STAT3 is tyrosine phosphorylated in vivo in CTCL skin lesions and in 65 
peripheral blood Sézary cells. The level of tyrosine phosphorylation in STAT3 increases in advanced 66 
disease
13,24
. Activating mutations are sufficient to turn STAT3 into a full oncogene in experimental 67 
animals
10
 and activating mutations in JAKs have been described in other hematological 68 
malignancies
25-27
. Recently, activating mutations have also been described in a subset (12,5%) of CTCL 69 
patients
28,29
, but it remains unknown what drives aberrant activation of Jak/STAT signaling in the 70 
majority of patients  STAT3 activation may become further increased following loss of regulatory 71 
control by SOCS3, Protein Inhibitor of Activated STAT3 (PIAS3), and other tyrosine protein 72 
phosphatases
19,30
 However, presently it remains unclear what drives the dramatic increase and 73 
chronic activation of STAT3 in advanced CTCL. 74 
 75 
While the etiology of this malignancy remains unclear, recent studies report on a significant 76 
geographical and occupational clustering of patient cohorts
31-36
. Thus, cross-analysis of cancer 77 
databases in Texas identified several geographic clusters with a 5-20-fold increased CTCL incidence
37
. 78 
A potential etiologic agent is unknown, but the environmental factors appear to play an essential role 79 
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in CTCL pathogenesis
36,37
. For decades, microbes have been suspected to play a key role in CTCL – 80 
both as etiologic agents and as drivers of life threatening complications
22,38-42
. So far, firm evidence 81 
for a microbial etiology in CTCL is lacking
43,44
, but clinical data indicate that bacteria may play an 82 
important role in progression and mortality in advanced disease
39,40,45
. Whereas Staphylococcus 83 
aureus is a common commensal organism in healthy individuals, it is a major source of morbidity in 84 
CTCL, as it causes persistent skin and life-threatening systemic infections
39,42,46,47
 seen in 44% to 76% 85 
of patients with advanced CTCL 
40,45,48
.  86 
 87 
Staphylococcal enterotoxins (SEs), including the A type (SEA) are bacterial superantigens that 88 
circumvent normal antigen processing and recognition. SE binds directly to MHC class II molecules 89 
and crosslink T-cell receptors (TCR) by binding to their TCR-Vbeta chains (TCR-Vb) with very high 90 
affinity, which results in broad T-cell hyper-activation. Because SEs are only restricted by the TCR-Vb 91 
of the TCR complex, they can activate up to 20% of all naïve T cells
49
. The importance of SEs is 92 
emphasized by reports indicating that antibiotic therapy of staphylococcal infections in CTCL is 93 
associated with clinical improvement and, in some cases, remission of the lymphoma 
40,45,50
. However, 94 
the mechanisms involved in disease aggravation and progression mediated by S. aureus and SE are 95 
poorly understood. 96 
 97 
Here we report that SEA induces STAT3 activation and IL-17 expression in malignant T cells via 98 
engagement of non-malignant CD4 T cells. Our findings suggest that bacterial toxins play a central role 99 
in the activation of a key oncogenic pathway in CTCL.  100 
  101 
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Materials and Methods 102 
Antibodies and reagents 103 
ELISA kits and IL-2, IL-7 and IL-15 blocking antibodies were purchased from R&D Systems 104 
(McKinley Place NE, MN, USA). JAK3 and Erk1/2 antibodies (Ab) were obtained from Santa Cruz 105 
Biotechnology (Santa Cruz, CA), while Stat3 Ab was purchased from Cell Signaling Technology 106 
(Beverly, MA, USA). Fluorochrome-conjugated CD3, CD4, CD25, CD26, MHC class II, pY(705)-Stat3 and 107 
the respective fluorochrome-conjugated isotype control Abs used for FACS were provided by R&D 108 
Systems, Biolegend (San Diego, CA, USA), BD Biosciences (San Jose, CA, USA) and Leinco (St. Louis, 109 
MO, USA), respectively. Other reagents were obtained as described below: TCR vβ kit from Ramcon 110 
(Bregnerød, Denmark), JAK3 inhibitor Tofacitinib (CP-690550) from Selleck Chemicals (Houston, TX, 111 
USA), siRNA against JAK3 and Stat3 from ThermoFisher Scientific (Waltham, MA, USA), SEs from Toxin 112 
Technology (Sarasota, FL, USA). SEA- mutants were generously provided by Active Biotech (Lund, 113 
Sweden). 114 
Patients and isolation of SA bacteria  115 
Malignant and non-malignant T cells were isolated from the blood of patients diagnosed with 116 
Sézary syndrome (SS) in accordance with the WHO-EORTC classification.
1
 Malignant SS T cells typically 117 
lack the expression of cell surface markers CD26 and/or CD7 and often display reduced expression of 118 
CD4 when compared with non-malignant T cells
1,51,52
. Accordingly, T cells were identified as malignant 119 
(CD4
low/+
CD7
-
, CD4
low/+
CD26
-
) and non-malignant (CD4
+
CD7
+
, CD4
+
CD26
+
). Bacterial isolates were 120 
collected from CTCL patients using swabs wetted with 0.1% Triton X-100 in 0.075 M phosphate buffer, 121 
transferred to Stuart´s medium, and cultivated on blood agar overnight at 37ºC at 5% CO
2
. In 122 
accordance with the Declaration of Helsinki, the samples were obtained with informed consent and 123 
after approval by the Committee on Health Research Ethics 124 
Cell lines 125 
The malignant T-cell line, SeAx, and the non-malignant T-cell line, MF1850, were established 126 
from patients diagnosed with CTCL
53
 and cultured in media supplemented with 10% human serum (HS 127 
medium) and IL-2 as described elsewhere
54
. Prior to experimental setup, the CTCL cell lines were 128 
starved overnight in HS medium without IL-2.  129 
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ELISA 130 
The concentrations of IL-17A in cell culture supernatants were measured using human IL-17A 131 
DuoSet ELISA development kit from R&D Systems (McKinley Place, NE, MN, USA) in accordance with 132 
the manufacturer’s instructions. 133 
Detection of Staphylococcal enterotoxins in bacterial isolate supernatants 134 
The presence of Staphylococcal enterotoxins in bacterial cultures was examined using the 135 
RIDASCREEN SET A, B, C, D, E kit (R-Biopharm AG, Darmstadt, Germany) with a detection limit of 0.25 136 
ng toxin/mL and in accordance with the manufacturer’s instructions.  137 
RNA purification, cDNA synthesis and QPCR 138 
Total cellular RNA was purified and reverse transcribed into complementary DNA as previously 139 
described
55
. qPCR was performed using the TaqMan assay from ThermoFisher Scientific in accordance 140 
with the manufacturer’s instructions and the samples were analyzed on an Mx3005P (Stratagene).  141 
Cell isolation, Flow cytometry, and cell sorting 142 
PBMCs were isolated from the blood of SS patients by Lymphoprep (Axis-shield, Oslo, Norway) 143 
density gradient centrifugation and used directly for flow cytometric analysis
56
 or cultured in HS 144 
media with PBS or SEA or sorted by FACS using FACSAria (BD Bioscences) into populations of 145 
malignant and non-malignant T cells based on CD4 and CD26 surface expression and then mono- or 146 
co-cultured in HS media with PBS or SEA. Purity of the sorted malignant and non-malignant T cells was 147 
higher than 99% and 95% respectively. In experiments where co-cultured SeAx and MF1850 cells were 148 
sorted, the SeAx cells were stained prior culture with 1 µM CSFE as previously described.
24
 The CSFE-149 
positive (SeAx) and negative (MF1850) cells were sorted by FACSAria resulting in a purity of more than 150 
98%. Data acquisition and flow cytometric analysis were done on Fortessa flow cytometers (from BD 151 
Biosciences) using FlowJo software (Tree Star, Ashland, OR). 152 
Transient transfections 153 
2 x10
6
 cells per sample were transfected with small interfering RNA (siRNA) against JAK3, 154 
STAT3 or non-targeting control (ON-TARGETplus SMARTpool, Thermo Scientific, Lafayette, CO, USA). 155 
Pellets were resuspended in 100uL transfection solution (Ingenio Electroporation solution, Mirus Bio, 156 
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Madison, WI, USA) in the presence of 0,25 µM of the respective siRNAs and transfected with an 157 
Amaxa Nucleofector (Amaxa GmbH, Cologne, Germany).  158 
Statistics 159 
For statistical analysis a two-tailed Student’s t-test with a significance level of p = 0.05 was 160 
used. A significant difference (p < 0.05) between a sample and control is indicated with an asterisk. 161 
  162 
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Results 163 
SE- containing bacterial isolates from CTCL skin trigger expression of IL-17 by malignant cells. 164 
It has been a matter of controversy whether or not malignant T cells express IL-17 in CTCL. 165 
Thus, some studies have reported on IL-17A and/or IL-17F expression by malignant T cells in lesional 166 
skin or blood
21,57-60
 whereas others did not find IL-17 family cytokines despite the presence of IL-22 167 
producing TH17 cells
61
. Since IL-17 is typically produced by CD4 T cells in response to bacteria such as 168 
S. aureus (reviewed in
62
) and SE-producing S. aureus often colonizes lesional skin, we hypothesized 169 
that SE can trigger IL-17 expression in CTCL. Accordingly, we tested whether bacterial isolates from 170 
lesional skin induced IL-17 production in co-cultures of malignant and non-malignant T cells. We 171 
analyzed for the presence of common enterotoxins in 46 bacterial isolates from CTCL skin (N= 6) and 172 
found that SEA was present in 21 out of 46 isolates, whereas SEB, SEC, SED and TSST-1 were not 173 
detected, therefore, confirming previous findings by others that lesional skin is often colonized by 174 
SEA-producing staphylococci
40
 175 
Next, we performed co-cultures of malignant T and non-malignant T-cell lines stimulated with 176 
SEA positive and negative bacterial isolates from CTCL skin. As shown in Fig. 1A, SEA containing 177 
isolates stimulated vigorous production of IL-17A protein (average value 1515 pg/ml; range 485 – 178 
3865 pg/ml, Fig. 1A, right panel), whereas SEA-negative bacterial isolates did not (average value 195 179 
pg/ml; range 100-250 pg/ml; Fig. 1A, left panel). In order to address, whether malignant and/or non-180 
malignant T cells produced IL-17, we stimulated co-cultures and separate cultures of malignant and 181 
non-malignant T cells in the presence or absence of SEA containing isolates prior to analysis of IL-17 182 
protein in culture supernatants. As shown in Fig. 1B, SEA positive isolates induced a strong IL-17 183 
response in co-cultures of malignant and non-malignant T-cell lines (Fig. 1B, right panel) whereas IL-17 184 
production was not observed in separate cultures of malignant and non-malignant T cells, respectively 185 
(Fig. 1B, middle and left panels). The SEA-negative isolates induced only weak IL-17 response. 186 
Considering that SEA was by far the most prevalent SE in bacterial isolates from our patients, we 187 
tested whether recombinant SEA can also induce IL-17 production in co-cultures of malignant and 188 
non-malignant T-cells. Indeed, recombinant SEA produced almost identical results as presented in 189 
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Figure 1B. Notably, two non-stimulatory SEA-mutants (SEAAF47 and SEAD227/AF47
63
 and SEB, SEC, 190 
SED, and TSST did not elicit significant IL-17 production (Fig. 1D) indicating that the IL-17 response was 191 
highly specific for intact SEA. The JAK3/STAT3 pathway drives IL-17 expression in malignant T cells
21
, 192 
and as shown in Fig 1E, a clinical-grade JAK3 inhibitor Tofacitinib profoundly (> 70%) inhibited SEA- 193 
induced IL-17 production in co-cultures of malignant and non-malignant T cells. 194 
SEA induces STAT3 activation in co-cultures. 195 
As shown in Fig. 2, SEA induced a strong up-regulation and phosphorylation (pY705) of STAT3 196 
in both malignant and non-malignant T cells following co-culture (Fig. 2, right panel) when compared 197 
to co-cultures stimulated with a vehicle control (Fig. 2, left panel). STAT3 phosphorylation was also 198 
increased in non-malignant T cells but not in malignant T cells following monoculture with SEA (Fig. 2, 199 
right panel) when compared to vehicle control (Fig. 2, left).  200 
To address whether IL-17 in co-cultures originated from malignant cells, non-malignant cells, 201 
or both cell types, we separated the malignant and non-malignant T cells by Fluorescence-Activated 202 
Cell Sorting (FACS) after co-culture in the presence or absence of SEA as above and measured IL-17    203 
As shown in Fig. 3A, SEA induced high expression of IL-17 mRNA in malignant T cells following co-204 
culture with non-malignant T cells (Fig. 3A, right) when compared to vehicle control (Fig. 3A right). In 205 
contrast, SEA did not induce significant IL-17 mRNA expression in non-malignant T cells following co-206 
culture with malignant T cells (Fig. 3A). Likewise, SEA did not induce IL-17 mRNA expression in 207 
monocultures of malignant and non-malignant T cells (Fig. 3A).  As shown in Fig. 3B, siRNA-mediated 208 
depletion of STAT3 in malignant T cells profoundly inhibited IL-17 production in co-cultures of 209 
malignant and non-malignant T cells (Fig. 3B, third column) when compared to the effect of a non-210 
targeting siRNA controls (Fig. 3B, first column). In contrast, STAT3 knockdown in non-malignant T cells 211 
had no effect on IL-17 production (Fig. 3B, second column) and STAT3 depletion in both malignant and 212 
non-malignant T cells had no additional effect when compared to siRNA-mediated depletion of STAT3 213 
in malignant T cells alone (Fig. 3B, third versus fourth column). In parallel, malignant and non-214 
malignant T cells were treated with JAK3 siRNA or a non-targeting control (NT) prior to co-culture in 215 
the presence or absence of SEA as above. JAK3 depletion in malignant T cells strongly inhibited IL-17 216 
production in co-cultures (Fig. 3C) whereas JAK3 depletion in non-malignant T cells had no effect 217 
For personal use only.on January 14, 2016. by guest  www.bloodjournal.orgFrom 
10 
 
indicating that SEA drives IL-17 expression through a JAK3/STAT3 dependent pathway in malignant T 218 
cells co-cultured with non-malignant T cells.  219 
To address whether the cell cross-talk dependent induction of IL-17 requires cell-to-cell 220 
contact or was mediated through soluble factors, malignant and non-malignant T cells were co-221 
cultured as above but separated by a cytokine-permeable membrane in Trans-Well plates. SEA 222 
induced high levels of IL-17 protein in supernatants isolated from malignant and non-malignant T 223 
cells, co-cultured in Trans-well plates (Fig. 3D). Likewise, SEA induced a significant increase in IL-17 224 
mRNA expression in malignant T cells, but not in the non-malignant T cells following co-culture in 225 
Trans-well plates (Fig. 3E). Since IL-2 induces IL-17 expression in malignant T cells
21
 and SEA induces 226 
IL-2 expression in non-malignant T cells
22
, co-cultures were performed with and without SEA and IL-2 227 
blocking and control antibody. As shown in Fig. 3F, inhibition of IL-2 almost completely blocked IL-17 228 
production in co-cultures indicating the key role of IL-2 in SEA-mediated cross-talk between malignant 229 
and non-malignant T cell lines.. 230 
STAT3 activation and IL-17 expression in primary T cells from CTCL patients.  231 
To address whether SEA also triggered STAT3 activation and IL-17 expression in primary T cells 232 
derived from CTCL patients, peripheral blood mononuclear cells (PBMC) were cultured in the 233 
presence or absence of SEA prior to FACS analysis of STAT3 activation in malignant (CD4
+
/CD26
-
) and 234 
non-malignant (CD4
+
/CD26
+
) T-cell populations. As observed from pY(705)-Stat3 staining, SEA induced 235 
a profound activation of STAT3 in both malignant (CD4
+
/CD26
-
, Fig. 4A upper panel) and non-236 
malignant T cells (CD4
+
/CD26
+
, Fig. 4A, lower panel). Analysis of IL-17 expression showed induction of 237 
both mRNA (Fig. 4B) and protein (Fig. 4C) demonstrating significant IL-17A upregulation by SE in five 238 
out of six patients tested. 239 
To further investigate SEA- mediated activation of primary malignant T cells, we performed 240 
TCR Vb staining of malignant (CD4
+
/CD26
-
) and non-malignant (CD4
+
/CD26
+
) T-cell compartments. As 241 
shown in a representative image in Fig. 5A, CD4
+
/CD26
-
 T cells expressed only the TCR-Vb17, whereas 242 
CD4
+
/CD26
+
 T cells displayed a typical Gaussian distribution of TCR-Vb indicating that the CD4
+
/CD26
-
 243 
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compartment consisted of only one malignant T cell clone whereas the CD4
+
/CD26
+
 compartment 244 
contained a non-malignant T-cell population with a normal TCR-Vb distribution (Fig. 5A).  245 
Using FACS, we separated CD4
+
/CD26
-
 and CD4
+
/CD26
+
 T cells and performed mono- and co-246 
cultures with or without SEA prior to analysis of STAT3 phosphorylation. As shown in Fig. 5B, both 247 
malignant and non-malignant T cells displayed a considerable baseline STAT3 phosphorylation in 248 
primary malignant and non-malignant T cells, which is in agreement with our previous findings
13
. 249 
Notably, SEA triggered a profound up-regulation of STAT3 phosphorylation in malignant T cells after 250 
co-culture with non-malignant T cells and in the presence of SEA (Fig. 5B), whereas SEA had little 251 
effect on STAT3 phosphorylation in monoculture of malignant T cells (Fig. 5B). In contrast, SEA 252 
induced a strong up-regulation of STAT3 phosphorylation in non-malignant T cells and this 253 
phosphorylation level was not further affected by addition of malignant T cells (Fig. 5B). 254 
To address whether SEA triggered IL-17 expression in primary malignant T cells, PBMCs were 255 
cultured with and without SEA prior to qPCR analysis of IL-17A expression in CD4
+
/CD26
-
 malignant T 256 
cells (Fig. 6A, lower right) and CD4
+
/CD26
+
 non-malignant T cells (Fig. 6A, upper right). Notably, SEA 257 
induced IL-17A expression in both the large fraction (86%) of malignant T cells and the small fraction 258 
(5%) of non-malignant T cells (Fig. 6A, left versus right). Next, malignant T cells (CD4
+
/CD26
-
) were 259 
cultured in the presence and absence of SEA in monoculture and co-culture with non-malignant CD4 T 260 
cells. As shown in Fig.6B, SEA induced IL-17 production in primary malignant T cells only when co-261 
cultured with non-malignant T cells, but not in monocultures of malignant T cells (Fig. 6B) showing 262 
that IL-17A expression in primary malignant T cells depended on SEA-driven cross-talk between 263 
malignant and non-malignant T cells. Next, co-cultures were treated with neutralizing antibodies 264 
against IL-2, IL-7, IL-15, (and a combination of the three antibodies), prior to stimulation with SEA. As 265 
shown in Fig. 6C, each individual antibody inhibited the IL-17A response by 15-20%, whereas the 266 
combination of antibodies inhibited the response by more than 40% (Fig. 6C) indicating the IL-17A 267 
response was at least partly driven by IL-2Rg cytokines.  268 
 269 
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  270 
Discussion 271 
In this study we demonstrate for the first time that SEA induces STAT3 activation and IL-17 272 
expression in immortalized and primary malignant T cells derived from CTCL patients. SEA-containing 273 
isolates of bacteria from CTCL skin, as well as recombinant SEA, triggered STAT3 activation and a 274 
robust IL-17 production in malignant T cells when co-cultured with non-malignant T cells but not with 275 
SEA alone. Activated STAT3 is oncogenic in animal models
10
 and believed also to foster CTCL
12-17
. 276 
STAT3 provides survival signals through up-regulation of proto-oncogenes such as Bcl-2 and 277 
survivin
11,15
, Interleukin-2 receptor (IL2R)
64
 and pro-oncogenic miRNAs
65,66
 and down-regulation of 278 
tumor suppressive miRNAs such as miR-22
67
. In addition, STAT3 drives expression of Suppressor of 279 
Cytokines Signaling (SOCS)
19
, cytokines of the TH2 (IL-5 and IL-13)
68
, TH17 (IL-17, IL-22)
21
, regulatory T-280 
cell (IL-10) phenotype
22
, and other factors.  281 
Our finding that SEA induced strong STAT3 activation in primary malignant T cells provides 282 
direct evidence linking bacterial toxins with activation of an oncogene in CTCL. Moreover, it suggests a 283 
mechanism whereby toxin-producing bacteria – via the activation of STAT3 - can augment an array of 284 
pathological processes in the lymphomagenesis. This is important because staphylococcal 285 
enterotoxins for decades have been suspected to play a tumor-promoting role in CTCL
39,40,45,50,69-71
. 286 
We now propose that SEA-mediated cross-talk between malignant and non-malignant T cells triggers 287 
oncogenic STAT3 activation in vivo. Our findings provide a plausible explanation for clinical 288 
observations indicating that SE-producing staphylococci promote tumor growth and aggravate the 289 
disease and, reversely, that antibiotic therapy may halt disease progression and even induce tumor 290 
regression in some CTCL patients
40,45,50
. 291 
 292 
Despite the well-established role of STAT3 in CTCL pathogenesis, it has not been clear what 293 
drives malignant STAT3 activation in vivo. Recently, activating mutations have been described in a 294 
subset (12,5%) of CTCL patients
28,29
, but it remains unknown what drives aberrant STAT3 activation in 295 
the majority of patients. Early on it was discovered that malignant T cells under ex vivo conditions 296 
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rapidly lost expression of activated STAT3 indicating that in vivo signals and factors (such as IL-2Rg 297 
cytokines) present by the local environment play a key role in malignant STAT3 activation in CTCL 298 
patients
14
. In support, IL-2 and other IL-2Rg- binding cytokines like IL-7, IL-15, and IL-21 induce STAT3 299 
activation in primary malignant T cells and immortalized T-cell lines
72-74
 suggesting that these 300 
cytokines may also drive STAT3 activation in vivo.  Although, both malignant and non-malignant T cells 301 
as well as stromal cells and keratinocytes may produce IL-2R-binding cytokines in vivo, the actual cells 302 
producing these factors and relative contribution by different sources remain unknown. 303 
  304 
The present findings showing that SEA triggers STAT3 activation and IL-17 expression via an 305 
indirect mechanism involving non-malignant (i.e. infiltrating) T cells and soluble factors such as IL-2 306 
and other IL-2Rg cytokines suggest that enterotoxins may also trigger IL-2Rg-mediated STAT3 307 
activation in vivo. SE-producing S. aureus skin infection is more common in advanced disease when 308 
compared to less advanced CTCL. In fact, S. aureus was isolated from skin, blood, and other foci from 309 
the majority of CTCL patients with advanced disease and in half of these patients, the bacteria 310 
produced SEA, SEB, and/or TSST
40
. If the proposed mechanism is at play in these patients, higher loads 311 
of SE-producing bacteria in skin and blood in advanced disease would be predicted to translate into 312 
higher levels of activated STAT3 and may partially explain why malignant STAT3 activation is increased 313 
in advanced disease
13
. 314 
 315 
As mentioned above, staphylococcal enterotoxins have for long been suspected to drive 316 
chronic activation of malignant T cells
40,50,69-71,75
. Originally, it was thought that toxins triggered 317 
proliferation and expansion of malignant T cells through a direct binding and activation of malignant 318 
T-cell clones expressing the appropriate TCR-Vb but little data was available to support this 319 
hypothesis, while others contradicted it (reviewed in 
38
). Our findings presented in this study have 320 
significant implications for our understanding of the interplay between bacterial toxins and malignant 321 
T cells. An indirect mode of action implies that toxin-mediated activation of malignant T cells does not 322 
rely on the expression of a single, toxin-specific TCR-Vb by these malignant T cells but on expression 323 
of multiple toxin-binding TCR-Vb expressed by non-malignant T infiltrating cells. Consistent with this 324 
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hypothesis, we observed that SEA induced STAT3 activation in a primary malignant T-cell clone 325 
expressing a SEA-non-responsive TCR-Vb (TCR-Vb17) only when co-cultured with non-malignant T 326 
cells expressing a full TCR-Vb repertoire including several SEA-binding TCR-Vb (such as TCR-Vb5).  327 
In principle, this implies that not only a few patients harboring a single malignant T-cell clone 328 
expressing a SEA-responsive TCR-Vb, but all patients carrying non-malignant T cells with SEA- 329 
responsive TCR-Vb are susceptible to SEA- mediated STAT3 activation in malignant T cells. Thus, 330 
bacterial toxins might have a dramatic impact on malignant T cell activation in a much broader range 331 
of patients than previously thought. Moreover, our findings show that malignant T cells engage in a 332 
complex and delicate cross-talk with non-malignant T cells, which dramatically changes their response 333 
to signals and factors in the microenvironment. By inference, our data therefore indicate that 334 
conventional in vitro models using monocultures of purified malignant T cells have fundamental 335 
limitations, when it comes to mimicking the pathogenesis in vivo. Furthermore, it is likely that 336 
cytokines and factors other than IL-2Rg cytokines also influence toxin-mediated cross-talk between 337 
malignant and non-malignant T cells. Indeed, SEA triggers IL-10 expression in co-cultures of malignant 338 
and non-malignant T cells
76
, IL-13 inhibits IL-17 but not IL-22 and IL-26 expression by TH17 cells
77
, and 339 
prostaglandins such as PGE2 produced by malignant T cells are known to modulate differentiation and 340 
cytokine production by non-malignant T cells
76
. Accordingly, our data suggest that an inclusion of non-341 
malignant T cells and possibly stromal cells and keratinocytes into cultures of malignant T cells would 342 
critically improve future in vitro models of CTCL to better mimic the dynamic interactions seen in CTCL 343 
patients. 344 
 345 
It has been a matter of controversy whether or not IL-17 is expressed in CTCL. Some studies 346 
have reported IL-17 mRNA and/or protein expression in situ and ex vivo, whereas others reported its 347 
absence, despite the presence of IL-22 producing TH17-like cells
21,57-59,61
. The present findings offer a 348 
possible explanation for these opposite results. Specifically, that the differences in frequency and 349 
severity of skin colonization and infection by SE- producing bacteria between different cohorts of 350 
patients and even within a single cohort may explain why IL-17 expression differed between these 351 
studies and between patients within a single cohort
21,57,61
. The finding that SEA induces IL-17 352 
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expression in non-malignant primary T cells was not unexpected given that SEA mediates STAT3 353 
activation in these cells
78
, but important as it suggests that both malignant and non-malignant T cells 354 
may contribute to IL-17 expression in vivo. As psoriasis is also associated with IL-17, de-regulated 355 
STAT3 signaling, and skin colonization by superantigen- producing bacteria like staphylococcus aureus, 356 
it is tempting to speculate that similar pathological mechanisms are involved in psoriasis and CTCL – 357 
disorders, which have many histological and clinical features in common. Yet, it is an open question 358 
whether IL-17 is involved in the antimicrobial defense and/or lymphomagenesis in CTCL patients 359 
displaying skin colonization by enterotoxin producing staphylococcus aureus.   360 
 361 
In conclusion, we show that SEA induces a cross-talk-dependent activation of STAT3 and 362 
expression of IL-17 in malignant T cells suggesting a mechanism whereby SEA- producing bacteria 363 
promote activation of an established oncogenic pathway (STAT3) previously implicated in the 364 
pathogenesis of CTCL.  365 
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Figure legends 549 
Figure 1. 550 
Bacterial isolates from CTCL patients contain staphylococcal enterotoxins. (A) Mixed bacterial 551 
isolates from patients were tested for SE expression (SEA, SEB, SEC, SED + TSST-1) and categorized 552 
accordingly as either positive or negative. Co-cultures with Malignant T cells (SeAx) and Non-553 
malignant T cells (MF1850) were then stimulated with SE-positive or SE-negative isolates and 554 
incubated for 24 hours. IL-17 concentration in the supernatants was determined by ELISA. (B) 555 
Malignant (SeAx) - and Non-malignant (MF1850) T cell lines were mono- and co-cultured in the 556 
absence (Media) or presence (Isolate) of a mixed bacterial isolate from a CTCL patient. IL-17A protein 557 
was measured in the supernatant after 24 hours of incubation with ELISA. (C) Malignant (SeAx) -  and 558 
Non-malignant (MF1850) T cell lines  were mono- and co-cultured with either vehicle (PBS) or (C) 559 
recombinant SEA (50 ng/mL) and (D) SEAwt or SEAD227A, SEAF47A/D227A, SEB, SEC2, SED, TSST-1 560 
toxins (50 ng/mL). IL-17A protein was measured in the supernatant after 24 hours of incubation with 561 
ELISA. (E) Malignant (SeAx) and non-malignant (MF1850) T cell lines were mono – and co-cultured 562 
with SEA (50 ng/ml) and Tofacitinib (0.3 µM) or vehicle (DMSO) for 24 hours. After incubation IL-17A 563 
protein concentration was determined by ELISA. Error bars represent SEM of three independent 564 
experiments. 565 
Figure 2. 566 
Staphylococcal enterotoxins activate and phosphorylate STAT3 in both malignant and non-567 
malignant T cells. (A) Representative flow cytometric analysis of CFSE stained Malignant - (SeAx) and 568 
Non-malignant T cell lines (MF1850) mono- and co-cultured with either vehicle (PBS) or recombinant 569 
SEA (50 ng/mL) for 24 hours. All samples were stained for pY(705)-Stat3. “PBS + Malignant” signifies 570 
gated Non-malignant T cells co-cultured with Malignant T cells and vice versa for “SEA + Non-571 
malignant”. 572 
Figure 3. 573 
Enterotoxin induces IL-17 production in co-cultured malignant T cells.  574 
(A) Malignant (SeAx) and non-malignant (MF1850) T cell lines were either mono-cultured or co-575 
cultured with vehicle (PBS) or SEA (50 ng/ml) for 16 hours. The co-cultured malignant and non-576 
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malignant T cells were sorted by FACS and the relative level of IL-17A and GAPDH mRNA were 577 
determined in all samples by qPCR. In each sample the level of IL-17A mRNA was normalized to that 578 
of GAPDH mRNA and it is depicted as fold change compared to mono-cultured malignant T cells with 579 
PBS. “Malign (Cocultured)” signifies IL-17A expression in malignant T cells co-cultured with non-580 
malignant T cells and vice versa for “Non-malign (Cocultured)”. (B) Malignant (SeAx) and non-581 
malignant (MF1850) T cells were transiently transfected with NT or Stat3-specific siRNA (B) or JAK3 582 
specific siRNA (C) and monocultured for 24 hours. Then, the transfected cells were washed and 583 
cocultured in the presence of SEA (50 ng/mL) for another 24 hours before the concentrations of IL-584 
17A in cell culture supernatants was determined by ELISA. Presented as percent of IL-17A secretion 585 
relative to cocultures of malignant and non-malignant T cells transfected with NT siRNA. (D) 586 
Malignant (SeAx) and non-malignant (MF1850) T cell lines were co-cultured separated by transwells 587 
with vehicle (PBS) or SEA (50 ng/ml) for 24h. IL-17 concentrations in the supernatants were 588 
determined by ELISA. (E) Malignant (SeAx) and non-malignant (MF1850) T cell lines were either mono-589 
cultured with transwells or co-cultured separated by transwells for 24h. The relative level of IL-17A 590 
and GAPDH mRNA were determined in all samples by qPCR. In each sample the level of IL-17A mRNA 591 
was normalized to that of GAPDH mRNA and it is depicted as fold change compared to mono-cultured 592 
malignant T cells with PBS. “Malign Transwell” signifies IL-17A expression in malignant T cells co-593 
cultured with non-malignant T cells separated by a transwell and vice versa for “Non-malign. 594 
Transwell”. (F) Malignant - (SeAx) and Non-malignant T cell lines (MF1850) were mono- and co-595 
cultured with either vehicle (PBS), SEA, SEA and IgG isotype control or SEA and neutralizing IL-2 596 
antibody. IL-17 concentrations in the supernatants were determined by ELISA. Error bars represent 597 
SEM of three independent experiments. 598 
Figure 4 599 
Staphylococcal enterotoxins treatment leads to STAT3 phosphorylation and subsequent IL-17 600 
secretion in primary T cells from CTCL patients. (A) Representative flow cytometric analysis of 601 
peripheral blood mononuclear cells freshly purified from a CTCL patient and cultured for 24 hours 602 
with SEA (200 ng/mL) or vehicle (PBS). After incubation cells were stained for py-Stat3 and CD3, CD4 603 
and CD26. Non-malignant T cells stain CD3
+
, CD4
+
, CD26
+
 and malignant T cells stain CD3
+
, CD4
+
, CD26
-
604 
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. (B) PBMCs from CTCL patients were stimulated with a cocktail of SEA, SEB, SEC2 SEE, SEI, TSST-1 (200 605 
ng/mL) (SE) or vehicle (PBS) for 24 hours. After incubation IL17A expression and GAPDH expression 606 
was determined by qPCR. In each sample IL17A expression is normalized to GAPDH. (C) Pooled data of 607 
PBMCs from CTCL patients stimulated for 24 hours with a cocktail of SEA, SEB, SEC2 SEE, SEI, TSST-1 608 
(200 ng/mL) (SE) or vehicle (PBS). IL-17A concentrations were determined by ELISA and normalized to 609 
10
6
 cells. * represents statistical significance of p<0.05. “ND”, No IL17A gene expression detected. 610 
Figure 5 611 
Staphylococcal enterotoxins induce Stat3 phosphorylation in primary malignant T cells cultured 612 
with non-malignant T cells. (A) Representative flow cytometric analysis of freshly purified PBMCs 613 
from a CTCL patient stained with CD3, CD4, CD26 and a TCR-Vbeta panel. Bar plot demonstrates TCR-614 
Vbeta repertoire of the malignant (CD3
+
, CD4
+
, CD26
-
) T cell compartment and the non-malignant 615 
(CD3
+
, CD4
+
, CD26
+
) compartment. (B) CD4
+
, CD26
-
 (malignant T cells) and CD4
+
, CD26
+
 (normal T cells) 616 
were separated by FACS from freshly purified PBMCs from a CTCL patient.  CD4
+
, CD26
-
 and CD4
+
, 617 
CD26
+
 T cells were mono - and co-cultured with either vehicle (PBS) or SEA (200 ng/mL) for 24 hours. 618 
After incubation cells were stained for pY-Stat3. Intensity of pY-Stat3 staining is shown in contour 619 
plot. “PBS + Non-malignant” signifies gated malignant T cells co-cultured with non-malignant T cells 620 
and stimulated with vehicle and vice versa for “SEA + Malignant” 621 
Figure 6  622 
Staphylococcal enterotoxins induce IL-17 production from cocultures of primary malignant T cells 623 
and non-malignant CD4 T cells. (A) PBMCs from a CTCL patient were stimulated with either vehicle 624 
(PBS) or SEA (200 ng/mL) for 24 hours and then sorted by CD4, CD26. IL17A gene expression from 625 
malignant and non-malignant cells were determined by qPCR and normalized to GAPDH expression. 626 
(B) Primary malignant T cells from a CTCL patient and non-malignant CD4 T cells were mono- and co-627 
cultured with either vehicle (PBS) or SEA (200 ng/mL). IL-17A protein was measured in the 628 
supernatant after 24 hours of incubation with ELISA. (C) Primary malignant T cells from a CTCL patient 629 
and non-malignant CD4 T cells were co-cultured with SEA and blocking antibodies against either IL-2, 630 
IL-7 or IL-15 or a combination of IL-2, IL-7 and IL-15 for 24 hours. IL-17A concentrations were 631 
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determined by ELISA and normalized to 10
6
 cells and shown in absolute concentrations and in percent 632 
inhibition of IC control. “ND”, No IL17A gene expression detected. 633 
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